Zelda Therapeutics (ASX: ZLD) (OTCQB: ZLDAF) recently announced collaborative research results indicating a new therapeutic target to treat HER2+ breast cancer.
The study was undertaken by Professor Cristina Sanchez, a member of Zelda’s Medical Advisory Board based at the Complutense University in Madrid, Spain, and was published in the Proceedings of the National Academy of Sciences.
Zelda’s CEO Dr Richard Hopkins said, “This paper makes an important contribution to our understanding of the role of the endocannabinoid system in cancer and has identified a novel therapeutic target for management of HER2+ breast cancer.
“Zelda is delighted to be collaborating with Professor Sanchez and her team. This study provides further validation of Zelda’s strategy to partner with the world’s leading researchers and represents an important step towards development of new cannabis-based therapies for treatment of cancer.”
HER2+ is a subtype of breast cancer that is characterised by the over-expressions of the oncogene HER2. Most patients with HER2+ breast cancer benefit from HER2-targeted treatments, however some do not respond and others develop resistance.
New treatment tools are therefore necessary for the treatment of this patient population. This study shows that the HER2 oncogene forms a relationship with the cannabinoid receptor CB2, which correlates with poor patient prognosis, and disrupting the relationship promotes anti-tumor responses.
Therefore, targeting this HER2-CBR relationship with Δ-9-tetrahydrocannabinol (THC), which binds the CB2 receptor, could be a positive treatment of HER2+ breast cancer.